Skip to content
Sarah Premji, MD· @SPremji7866 · X·· 2026-04-20Score60

olaparib

Reading

Next-generation ADCs: payload innovation

T-DXd is already rewriting the first-line standard.

Body

Dr. Elizabeth Lee reviews gapped schedule olaparib plus DS-8201a (T-DXd) in HER2 expressing tumors, endometrial and ovarian cancers, ORR 54%, mDOR 11.2 months, with durable disease control, sound rationale supporting synergism in a gapped schedule based on mechanism #AACR26
@AACR

Heat 10 · 6 likes · 0 replies · 4 reposts

Conference abstracts

Source: Sarah Premji, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org